A detailed history of Cloverfields Capital Group, LP transactions in Astrazeneca PLC stock. As of the latest transaction made, Cloverfields Capital Group, LP holds 32,533 shares of AZN stock, worth $2.13 Million. This represents 0.9% of its overall portfolio holdings.

Number of Shares
32,533
Previous 38,034 14.46%
Holding current value
$2.13 Million
Previous $2.97 Million 14.57%
% of portfolio
0.9%
Previous 1.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$76.67 - $87.62 $421,761 - $481,997
-5,501 Reduced 14.46%
32,533 $2.53 Million
Q2 2024

Aug 13, 2024

BUY
$66.81 - $80.83 $22,782 - $27,563
341 Added 0.9%
38,034 $2.97 Million
Q1 2024

May 14, 2024

BUY
$61.03 - $69.57 $25,937 - $29,567
425 Added 1.14%
37,693 $2.55 Million
Q4 2023

Feb 12, 2024

BUY
$61.89 - $69.28 $735,067 - $822,838
11,877 Added 46.78%
37,268 $2.51 Million
Q2 2023

Aug 14, 2023

BUY
$69.91 - $75.81 $1.21 Million - $1.31 Million
17,279 Added 213.01%
25,391 $1.82 Million
Q1 2023

Sep 07, 2023

SELL
$63.15 - $71.6 $659,286 - $747,503
-10,440 Reduced 41.12%
14,951 $1.04 Million
Q1 2023

May 12, 2023

BUY
$63.15 - $71.6 $4,294 - $4,868
68 Added 0.85%
8,112 $563,000
Q2 2022

Aug 12, 2022

SELL
$59.26 - $71.14 $230,106 - $276,236
-3,883 Reduced 32.56%
8,044 $531,000
Q1 2022

May 12, 2022

SELL
$55.72 - $67.12 $73,438 - $88,464
-1,318 Reduced 9.95%
11,927 $791,000
Q3 2021

Nov 12, 2021

BUY
$55.56 - $60.79 $3,444 - $3,768
62 Added 0.47%
13,245 $795,000
Q2 2021

Aug 12, 2021

BUY
$48.42 - $60.18 $7,166 - $8,906
148 Added 1.14%
13,183 $790,000
Q1 2021

May 13, 2021

BUY
$47.16 - $54.44 $13,016 - $15,025
276 Added 2.16%
13,035 $648,000
Q4 2020

Feb 16, 2021

BUY
$48.52 - $58.02 $619,066 - $740,277
12,759 New
12,759 $638,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $203B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Cloverfields Capital Group, LP Portfolio

Follow Cloverfields Capital Group, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cloverfields Capital Group, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cloverfields Capital Group, LP with notifications on news.